A synthetic peptide containing amino acids 77 to 95 of the intracellular GTPase RhoA has previously been shown to inhibit replication of respiratory syncytial virus (RSV) in cultured cells. We show that residues 80 to 90 of RhoA are sufficient for this activity and that the cysteine residue at position 83 is critical. Further studies with an optimal peptide sequence containing amino acids 80 to 94 of RhoA revealed that the antiviral potency of the peptide is dependent on the oxidation of cysteine 83. Size-exclusion chromatography and sedimentation equilibrium studies of the peptide comprising residues 80 to 94 revealed that it is capable of forming aggregates in both reduced and oxidized states. A peptide (83A) in which the cysteine residue is replaced by an alanine does not form dimers or higher-order aggregates and did not inhibit RSV replication at any concentration tested. These data indicate that formation of peptide multimers is necessary for the antiviral activities of RhoA-derived peptides and suggest that the observed antiviral activities of these peptides may be unrelated to the biological functions of their parent molecule.Respiratory syncytial virus (RSV) is an enveloped, negativesense, single-stranded RNA virus of the Paramyxovirus family. It is the most important cause of lower respiratory tract infections in children worldwide and is a significant cause of morbidity and mortality among immunocompromised adults and the institutionalized elderly (4). RSV enters host cells by fusing its viral envelope with the host cell plasma membrane to allow penetration of the viral nucleocapsid. The processes of viral attachment and fusion are mediated by the viral glycoproteins, termed the fusion protein (F), glycoprotein (G), and the small hydrophobic protein (SH). While G and SH can increase the efficiency of the viral entry process, F alone is sufficient (10,13,27).It has previously been observed that RSV F can interact with the small GTPase RhoA (20) and that a peptide derived from the F-binding region of RhoA is able to block the entry of RSV into susceptible host cells (21). This peptide, which we termed peptide 77-95, comprises the linear peptide sequence corresponding to amino acids (aa) 77 to 95 of RhoA. On the basis of the observation that peptide 77-95 can interfere with binding of F to RhoA in an in vitro enzyme-linked immunosorbent assay (ELISA), it was originally hypothesized that peptide 77-95 may inhibit an interaction between RSV F and RhoA essential to F-mediated membrane fusion (21). However, an in vivo interaction between F and RhoA at the time of viral entry has not been demonstrated. In addition, other agents that should be capable of inhibiting a RhoA-F interaction, such as anti-RhoA antibodies and exogenous, purified RhoA, have no inhibitory effect on RSV entry (unpublished data). Thus, the ability of the RhoA-derived peptide to inhibit RSV entry may be unrelated to its ability to disrupt an in vitro F-RhoA interaction.The region from aa 77 to 95 of RhoA corresponds to an internal beta st...